Akari Therapeutics (AKTX) Other Accumulated Expenses (2018 - 2026)
Akari Therapeutics recorded quarterly Other Accumulated Expenses of $505000.0 in Q1 2026, up 12.47% quarter-over-quarter from $449000.0 in Q4 2025, and down 36.56% year-over-year from $796000.0 in Q1 2025.
Akari Therapeutics' Other Accumulated Expenses history runs 6 years deep, the most recent figure standing at $505000.0 for Q1 2026.
- In Q1 2026, Other Accumulated Expenses fell 36.56% year-over-year to $505000.0; the TTM figure through Mar 2026 stood at $505000.0 (down 36.56% YoY), while the FY2025 annual figure was $449000.0, down 38.58% from the prior year.
- Other Accumulated Expenses came in at $505000.0 for Q1 2026 at Akari Therapeutics, up from $449000.0 in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $983000.0 in Q1 2024 to a low of $41000.0 in Q2 2024.
- A 5-year average of $429545.5 and a median of $449000.0 in 2025 frame the typical range for Other Accumulated Expenses.
- On a YoY basis, Other Accumulated Expenses climbed as much as 1485.37% in 2025 and fell as far as 73.1% in 2025.
- Akari Therapeutics' Other Accumulated Expenses stood at $94000.0 in 2022, then fell by 20.21% to $75000.0 in 2023, then soared by 874.67% to $731000.0 in 2024, then plunged by 38.58% to $449000.0 in 2025, then rose by 12.47% to $505000.0 in 2026.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $505000.0, $449000.0, and $85000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 505,000.00 |
| Dec 31, 2025 | 424,000.00 |
| Sep 30, 2025 | 85,000.00 |
| Jun 30, 2025 | 260,000.00 |
| Mar 31, 2025 | 796,000.00 |
| Dec 31, 2024 | 731,000.00 |
| Sep 30, 2024 | 81,000.00 |
| Jun 30, 2024 | 653,000.00 |
| Mar 31, 2024 | 983,000.00 |
| Dec 31, 2023 | 94,000.00 |
| Dec 31, 2022 | 128,000.00 |
| Sep 30, 2018 | 29,792.00 |